Tin T. Win, M.D., Dismissal of Proceeding, 52802-52803 [2013-20676]
Download as PDF
52802
Federal Register / Vol. 78, No. 165 / Monday, August 26, 2013 / Notices
Dated: August 20, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–20724 Filed 8–23–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Cambridge Isotope Lab
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 01, 2013,
Cambridge Isotope Lab, 50 Frontage
Road, Andover, Massachusetts 01810,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Morphine (9300), a
basic class of controlled substance listed
in schedule II.
The company plans to utilize small
quantities of the listed controlled
substance in the preparation of
analytical standards.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such a substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR § 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than October 25, 2013.
Dated: August 15, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–20723 Filed 8–23–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
ehiers on DSK2VPTVN1PROD with NOTICES
Manufacturer of Controlled
Substances; Notice of Registration;
Morton Grove Pharmaceuticals
By Notice dated March 12, 2013, and
published in the Federal Register on
March 20, 2013, 78 FR 17231, Morton
Grove Pharmaceuticals, 6451 Main
Street, Morton Grove, Illinois 60053–
2633, made application by renewal to
the Drug Enforcement Administration
VerDate Mar<15>2010
13:45 Aug 23, 2013
Jkt 229001
(DEA) to be registered as a bulk
manufacturer of Gamma Hydroxybutyric
Acid (2010), a basic class of controlled
substance listed in schedule I.
The company plans to manufacture
the listed controlled substance for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Morton Grove Pharmaceuticals to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
investigated Morton Grove
Pharmaceuticals to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems; verification of the
company’s compliance with state and
local laws; and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic class of
controlled substance listed.
Dated: August 15, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–20761 Filed 8–23–13; 8:45 am]
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Navinta, LLC., to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated Navinta,
LLC., to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: August 15, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–20757 Filed 8–23–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Tin T. Win, M.D., Dismissal of
Proceeding
BILLING CODE 4410–09–P
On February 27, 2013, I, the
Administrator of the Drug Enforcement
Administration, issued an Order to
DEPARTMENT OF JUSTICE
Show Cause and Immediate Suspension
of Registration to Tin T. Win, M.D.
Drug Enforcement Administration
(hereinafter, Registrant), of Lake Havasu,
Arizona. GX 10, at 1. Among various
Manufacturer of Controlled
charges, the Order alleged that
Substances; Notice of Registration:
Registrant issued numerous controlled
Navinta, LLC
substance prescriptions after the
By Notice dated April 10, 2013, and
Arizona Medical Board had prohibited
published in the Federal Register on
her ‘‘from prescribing controlled
April 19, 2013, 78 FR 23596, Navinta,
substances’’ and thus violated both the
LLC., 1499 Lower Ferry Road, Ewing,
Board’s order and federal law. Id. at 1–
New Jersey 08618–1414, made
3 (citing Ariz. Rev. Stat. § 32–
application to the Drug Enforcement
1401(27)(r); 21 U.S.C. 841). The Order
Administration (DEA) to be registered as
also notified Registrant of her right to
a bulk manufacturer of the following
either request a hearing on the
basic classes of controlled substances:
allegations or submit a written
statement of position in lieu of a hearing
Drug
Schedule
within thirty (30) days of her receipt of
Pentobarbital (2270) .....................
II the Order, the procedure for electing
Remifentanil (9739) ......................
II either option, and the consequence of
failing to elect either option.
The company plans initially to
On March 6, 2013, the Order was
manufacture API quantities of the listed personally served on Registrant by a
controlled substances for validation
DEA Special Agent and a Diversion
purposes and FDA approval, then to
Investigator. See GX 11. On May 20,
produce commercial size batches for
2013, the Government filed a Request
distribution to dosage form
for Final Agency Action, which sought
manufacturers upon FDA approval.
the revocation of Registrant’s
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
E:\FR\FM\26AUN1.SGM
26AUN1
Federal Register / Vol. 78, No. 165 / Monday, August 26, 2013 / Notices
registration. Request for Final Agency
Action, at 12. Therein, the Government
represented that neither Registrant, nor
anyone purporting to represent her, had
filed either a request for a hearing or a
written statement in lieu of a hearing.
Id. at 2.
Upon review of the record, the
Government’s evidence showed that
Registrant’s registration was due to
expire on May 31, 2013. See GX 2.
However, because the filing of a timely
renewal application would have
prevented the expiration of her
registration (albeit in suspended status),
see 5 U.S.C. 556(e), I took official notice
of her registration record with the
Agency. According to that record,
Registrant did not file either a renewal
application or a new application. The
Agency therefore deemed her
registration as expired and retired her
registration number.
While ordinarily these findings render
a case moot, see Ronald J. Riegel, 63 FR
67132, 67133 (1998), simultaneously
with the issuance of the Order to Show
Cause, I immediately suspended
Registrant’s registration. Because the
Immediate Suspension Order also
authorized the Government to seize any
controlled substances in Registrant’s
possession, and thus created the
possibility that a collateral consequence
existed which precludes a finding of
mootness, see Robert Charles Ley, 76 FR
20033, 20034 (2011), I directed the
Government to notify my Office as to
whether it had seized any controlled
substances. Order (July 15, 2013).
On July 22, 2013, the Government
notified my Office that it had not seized
any controlled substances pursuant to
the Immediate Suspension Order. Gov.
Response Regarding Mootness, at 2. The
Government further acknowledged that
this ‘‘case is now moot.’’ Id.
Accordingly, I will dismiss this
proceeding. See Ley, 76 FR at 20034.
ehiers on DSK2VPTVN1PROD with NOTICES
Order
Pursuant to the authority vested in me
by 21 U.S.C. 824(a), as well as 28 CFR
0.100(b), I order that the Order to Show
Cause and Immediate Suspension of
Registration issued to Tin T. Win, M.D.,
be, and it hereby is, dismissed. This
Order is effective immediately.
Dated: August 16, 2013.
Michele M. Leonhart,
Administrator.
BILLING CODE 4410–09–P
13:45 Aug 23, 2013
Office of the Secretary
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request; Additional
Information Collection Requirements
for Special Dipping and Coating
Operations
ACTION:
Notice.
The Department of Labor
(DOL) is submitting the Occupational
Safety and Health Administration
(OSHA) sponsored information
collection request (ICR) titled,
‘‘Additional Information Collection
Requirements for Special Dipping and
Coating Operations,’’ to the Office of
Management and Budget (OMB) for
review and approval for continued use,
without change, in accordance with the
Paperwork Reduction Act (PRA) of 1995
(44 U.S.C. 3501 et seq.).
DATES: Submit comments on or before
September 25, 2013.
ADDRESSES: A copy of this ICR with
applicable supporting documentation;
including a description of the likely
respondents, proposed frequency of
response, and estimated total burden
may be obtained free of charge from the
RegInfo.gov Web site at https://
www.reginfo.gov/public/do/PRA
ViewICR?ref_nbr=201306–1218–003
(this link will only become active on the
day following publication of this notice)
or by contacting Michel Smyth by
telephone at 202–693–4129 (this is not
a toll-free number) or sending an email
to DOL_PRA_PUBLIC@dol.gov.
Submit comments about this request
to the Office of Information and
Regulatory Affairs, Attn: OMB Desk
Officer for DOL–OSHA, Office of
Management and Budget, Room 10235,
725 17th Street NW., Washington, DC
20503, Fax: 202–395–6881 (this is not a
toll-free number), email: OIRA_
submission@omb.eop.gov. Commenters
are encouraged, but not required, to
send a courtesy copy of any comments
to the U.S. Department of LaborOASAM, Office of the Chief Information
Officer, Attn: Information Management
Program, Room N1301, 200 Constitution
Avenue NW., Washington, DC 20210,
email: DOL_PRA_PUBLIC@dol.gov.
FOR FURTHER INFORMATION CONTACT:
Michel Smyth by telephone at 202–693–
4129 (this is not a toll-free number) or
by email at DOL_PRA_PUBLIC@dol.gov.
SUMMARY:
Authority: 44 U.S.C. 3507(a)(1)(D).
[FR Doc. 2013–20676 Filed 8–23–13; 8:45 am]
VerDate Mar<15>2010
DEPARTMENT OF LABOR
Jkt 229001
The
Dipping and Coating Operations
Standard requires employers to post a
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
52803
conspicuous sign near each piece of
electrostatic detearing equipment that
notifies employees of the minimum safe
distance they must maintain between
goods undergoing electrostatic detearing
and the electrodes or conductors of the
equipment used in the process. See 29
CFR 1910.126(g)(4). This information
collection is subject to the PRA. A
Federal agency generally cannot
conduct or sponsor a collection of
information, and the public is generally
not required to respond to an
information collection, unless it is
approved by the OMB under the PRA
and displays a currently valid OMB
Control Number. In addition,
notwithstanding any other provisions of
law, no person shall generally be subject
to penalty for failing to comply with a
collection of information that does not
display a valid Control Number. See 5
CFR 1320.5(a) and 1320.6. The DOL
obtains OMB approval for this
information collection under Control
Number 1218–0237. For additional
substantive information about this ICR,
see the related notice published in the
Federal Register on April 9, 2013 (78 FR
21159).
OMB authorization for an ICR cannot
be for more than three (3) years without
renewal, and the current approval for
this collection is scheduled to expire on
December 31, 2013. The DOL seeks to
extend PRA authorization for this
information collection for three (3) more
years, without any change to existing
requirements. It should also be noted
that existing information collection
requirements submitted to the OMB
receive a month-to-month extension
while they undergo review.
Interested parties are encouraged to
send comments to the OMB, Office of
Information and Regulatory Affairs at
the address shown in the ADDRESSES
section within 30 days of publication of
this notice in the Federal Register. In
order to help ensure appropriate
consideration, comments should
mention OMB Control Number 1218–
0237. The OMB is particularly
interested in comments that:
• Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
• Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
• Enhance the quality, utility, and
clarity of the information to be
collected; and
E:\FR\FM\26AUN1.SGM
26AUN1
Agencies
[Federal Register Volume 78, Number 165 (Monday, August 26, 2013)]
[Notices]
[Pages 52802-52803]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-20676]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Tin T. Win, M.D., Dismissal of Proceeding
On February 27, 2013, I, the Administrator of the Drug Enforcement
Administration, issued an Order to Show Cause and Immediate Suspension
of Registration to Tin T. Win, M.D. (hereinafter, Registrant), of Lake
Havasu, Arizona. GX 10, at 1. Among various charges, the Order alleged
that Registrant issued numerous controlled substance prescriptions
after the Arizona Medical Board had prohibited her ``from prescribing
controlled substances'' and thus violated both the Board's order and
federal law. Id. at 1-3 (citing Ariz. Rev. Stat. Sec. 32-1401(27)(r);
21 U.S.C. 841). The Order also notified Registrant of her right to
either request a hearing on the allegations or submit a written
statement of position in lieu of a hearing within thirty (30) days of
her receipt of the Order, the procedure for electing either option, and
the consequence of failing to elect either option.
On March 6, 2013, the Order was personally served on Registrant by
a DEA Special Agent and a Diversion Investigator. See GX 11. On May 20,
2013, the Government filed a Request for Final Agency Action, which
sought the revocation of Registrant's
[[Page 52803]]
registration. Request for Final Agency Action, at 12. Therein, the
Government represented that neither Registrant, nor anyone purporting
to represent her, had filed either a request for a hearing or a written
statement in lieu of a hearing. Id. at 2.
Upon review of the record, the Government's evidence showed that
Registrant's registration was due to expire on May 31, 2013. See GX 2.
However, because the filing of a timely renewal application would have
prevented the expiration of her registration (albeit in suspended
status), see 5 U.S.C. 556(e), I took official notice of her
registration record with the Agency. According to that record,
Registrant did not file either a renewal application or a new
application. The Agency therefore deemed her registration as expired
and retired her registration number.
While ordinarily these findings render a case moot, see Ronald J.
Riegel, 63 FR 67132, 67133 (1998), simultaneously with the issuance of
the Order to Show Cause, I immediately suspended Registrant's
registration. Because the Immediate Suspension Order also authorized
the Government to seize any controlled substances in Registrant's
possession, and thus created the possibility that a collateral
consequence existed which precludes a finding of mootness, see Robert
Charles Ley, 76 FR 20033, 20034 (2011), I directed the Government to
notify my Office as to whether it had seized any controlled substances.
Order (July 15, 2013).
On July 22, 2013, the Government notified my Office that it had not
seized any controlled substances pursuant to the Immediate Suspension
Order. Gov. Response Regarding Mootness, at 2. The Government further
acknowledged that this ``case is now moot.'' Id. Accordingly, I will
dismiss this proceeding. See Ley, 76 FR at 20034.
Order
Pursuant to the authority vested in me by 21 U.S.C. 824(a), as well
as 28 CFR 0.100(b), I order that the Order to Show Cause and Immediate
Suspension of Registration issued to Tin T. Win, M.D., be, and it
hereby is, dismissed. This Order is effective immediately.
Dated: August 16, 2013.
Michele M. Leonhart,
Administrator.
[FR Doc. 2013-20676 Filed 8-23-13; 8:45 am]
BILLING CODE 4410-09-P